Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA issues warning...

    USFDA issues warning letter to Megafine Pharma

    Written by savita thakur thakur Published On 2016-06-02T13:23:08+05:30  |  Updated On 2 Jun 2016 1:23 PM IST
    USFDA issues warning letter to Megafine Pharma

    NEW DELHI: The US health regulator has issued a warning letter to Mumbai-based Megafine Pharma for violations of good manufacturing norms, including data falsification and failure to prevent data manipulation at the company's Nashik plant.


    Summarising significant deviations from CGMP (current good manufacturing practice) norms at the Nashik facility, the US Food and Drug Administration (USFDA) said that its investigator observed several significant deviations.


    In the letter to company's director Hasmukh Gandhi, FDA said one of the company's analysts acknowledged falsifying test data and "substituted a reference standard chromatogram in place of the 12-month stability interval chromatogram".


    While the company had responded that its laboratory management did not discover the discrepancy until the 24-month stability interval and the batch quality was unaffected, the USFDA said the reply was inadequate as it did not address the extent of the data falsification that could exist in its laboratory.


    The USFDA further said one of the deviations was "failure to ensure that, for each batch of intermediate and API, appropriate laboratory tests are conducted to determine conformance to specifications."


    Another major violation of the current good manufacturing practice (CGMP) norms was the failure to prevent unauthorised access or changes to data and to provide adequate controls to prevent manipulation and omission of data, it added.


    Raising data integrity remediation issue, the letter said the quality system of Megafine Pharma "does not adequately ensure the adequacy and integrity of data to support the safety, effectiveness, and quality of drugs you manufacture".


    It also pulled up the company for conducting "inadequate investigation of critical deviations or a failure of a batch to meet its specifications or quality standards".


    It asked the company to do a comprehensive investigation into the extent of the inaccuracies in data records and reporting.


    The US health regulator said until the company corrected all the deviations and the compliance with CGMP is confirmed by it, USFDA "may withhold approval of any new applications or supplements listing your firm as an API manufacturer."


    Failure to correct these violations may also result in the USFDA continuing to refuse admission of articles manufactured at Megafine Pharma's Nashik plant, it added.

    Megafine PharmaUS Food and Drug AdministrationUSFDAUSFDA warning
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok